Compare Natera Inc. Common Stock (NTRA) vs Nuscale Power Corporation (SMR) Price & Performance

NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.

NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.

NuScale Power (SMR) trades at $6.495, down 3.06% on the day, reflecting ongoing operational losses and negative investor sentiment. The stock exhibits a bearish technical signal, with moving averages indicating strong selling pressure, though oversold oscillators suggest potential for a near-term bounce. Fundamentally, the company reported a net loss of $355.79M on revenue of $31.48M in 2025, with a deeply negative net income margin of -3,888.7% in 2026, highlighting severe profitability challenges despite operating in the high-potential nuclear energy sector.

The outlook remains highly speculative. Analyst consensus is a 'Buy' with a $11.25 price target, implying significant upside, but this is contingent on successful commercialization of its small modular reactor technology. Primary risks include persistent cash burn, intense competition, and the high capital and regulatory hurdles inherent in nuclear power development. The stock represents a high-risk, high-reward opportunity for investors betting on a future nuclear renaissance.